Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Company Overview
Nutriband Inc. is a specialized pharmaceutical company based in Oviedo, Florida, that focuses on cutting-edge transdermal and topical technologies. The company has built its expertise around developing a portfolio of innovative transdermal products, with a primary focus on its abuse-deterrent technology known as AVERSA. This proprietary technology integrates aversive agents into transdermal patches to prevent abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids and stimulants.
Core Business and Product Portfolio
The centerpiece of Nutriband’s portfolio is its lead product under development, an abuse-deterrent fentanyl patch that incorporates AVERSA technology. By employing a unique coating mechanism that leverages taste aversion, the patch is designed to deter the oral abuse of potent medications while ensuring that patients in need retain access to essential pain management solutions. The company also extends its technological expertise to other product categories, including transdermal consumer goods and a mosquito repellent patch, evidencing a diverse application of its platform.
Innovative Technology and Intellectual Property
Nutriband’s AVERSA technology is at the forefront of addressing the challenges posed by the global opioid crisis. The unique methodology of incorporating aversive agents, such as the well-known bitter compound Bitrex®, into patches is underpinned by a robust international intellectual property portfolio, with patents granted in 46 countries. This extensive protection not only reinforces the company’s market position but also demonstrates its commitment to innovation and drug safety.
Strategic Partnerships and Operational Excellence
The company has established strategic alliances with prominent partners in the pharmaceutical and manufacturing sectors. Its collaboration with Kindeva Drug Delivery enables Nutriband to integrate its abuse-deterrent technology into FDA-approved transdermal systems, thereby optimizing the manufacturing and regulatory pathway for its lead products. Additionally, Nutriband’s subsidiary, Pocono Pharma, bolsters its contract manufacturing services, distributing a variety of products to major retail channels across the United States.
Market Position and Business Model
Nutriband positions itself within a highly specialized niche of the pharmaceutical industry, focusing on transdermal applications that enhance drug safety while combating abuse potential. The company generates revenue primarily through the sale of its consumer transdermal products and contract manufacturing services, coupled with the anticipated benefits from its innovative abuse-deterrent technology. By streamlining regulatory processes and leveraging a single Phase 1 trial for its abuse-deterrent product, Nutriband demonstrates a pragmatic approach to market entry while ensuring rigorous compliance with safety standards.
Commitment to Safety and Market Impact
At its core, Nutriband is dedicated to addressing critical public health challenges by improving the safety profile of transdermal pharmaceutical products. The incorporation of AVERSA technology into products such as a fentanyl patch not only aims to reduce the risk of misuse and diversion but also helps prevent accidental exposure, which is particularly important in vulnerable populations. This dual focus on efficacy and safety underscores the company’s role in mitigating the impact of drug abuse while supporting the legitimate medical needs of patients.
Conclusion
Overall, Nutriband Inc. represents a blend of technological innovation, strategic operational partnerships, and a deep commitment to enhancing drug safety. Its comprehensive approach in leveraging abuse-deterrent transdermal technology sets it apart in a competitive industry. Investors and analysts looking for insights into innovative pharmaceutical strategies will find Nutriband’s focus on sustainable, safety-driven solutions to be of considerable significance.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced plans to offer contract manufacturing services for liquid-based topical products, following its recent cGMP certification. This certification relates to Pharmaceutical OTC GMP, 21 CFR Part 211/210, enhancing the company's manufacturing capabilities. CEO Gareth Sheridan stated that expanding these capabilities aligns with the company's revenue growth strategy for 2022. Nutriband is primarily focused on developing transdermal pharmaceutical products, including its abuse deterrent fentanyl patch utilizing AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its manufacturing subsidiary, Active Intelligence, has successfully received cGMP certification after a thorough audit. This certification is vital for expanding their contract manufacturing services on a national and international scale. CEO Gareth Sheridan highlighted that this achievement will enable the company to enhance its product offerings and explore new market opportunities, which are crucial for the company’s growth strategy.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its CEO Gareth Sheridan and President Serguei Melnik, accompanied by board members and senior management, will ring the NASDAQ Opening Bell on December 3, 2021, at 9:30 a.m. EST. Sheridan expressed gratitude for the teamwork and support that enabled the company’s journey so far. Nutriband focuses on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA™ technology. A live stream of the ceremony will be available online.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has launched the development of its lead product, AVERSA™ Fentanyl, aiming to create the world’s first abuse-deterrent fentanyl transdermal system. This initiative follows the company's uplisting to NASDAQ and new financing. The focus will include developing a commercial strategy, market assessment, and selecting a manufacturer to expedite market entry. CEO Gareth Sheridan emphasized the importance of improving safety while ensuring accessibility for patients. Nutriband specializes in transdermal pharmaceutical products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report on Bloomberg TV on November 13 at 7 p.m. ET. The program reaches approximately 73 million homes in the U.S. RedChip has 30 years of experience in small-cap investing commentary and interviews with public company executives.
Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA® technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the receipt of $2,062,500 from the exercise of 275,000 warrants at $7.50 each, linked to its earlier public offering on October 1, 2021. This adds to the $6,600,000 garnered from the sale of 1,056,000 shares, bringing the total gross proceeds to approximately $8,662,500 as of October 21, 2021. Nutriband focuses on developing transdermal pharmaceutical products, particularly an abuse deterrent fentanyl patch utilizing its AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has entered an exclusive manufacturing agreement with Diomics for its Diocheck™ technology, aimed at monitoring COVID-19 antibody levels. This transdermal patch provides results within 24 to 36 hours and remains effective for up to 14 days. The device is intended for assessing the effectiveness of COVID-19 vaccines over time, helping identify when boosters may be needed. The partnership showcases Nutriband's capabilities in innovative patch technologies, bolstering its position in the pharmaceutical market.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced an underwritten public offering of 1,056,000 units priced at $6.25 per unit, generating gross proceeds of $6.6 million. Each unit consists of one share of common stock and one warrant. The warrants are exercisable at $7.50 and expire in five years. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. This uplisting to the Nasdaq Capital Market aims to enhance visibility and support the company's strategic growth initiatives in developing transdermal pharmaceutical products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that it received a Notice of Allowance from the USPTO for patent application 16/707,547, focusing on its AVERSA® technology. This technology targets the prevention of opioid abuse, particularly for fentanyl patches. The announcement follows the company's initial NASDAQ listing and a $6.6 million underwritten offering on October 1, 2021. The proceeds will primarily fund the clinical development of AVERSA.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced its common stock and warrants began trading on the Nasdaq Capital Market on October 1, 2021. The company also priced an underwritten public offering of 1,056,000 units at $6.25 per unit, aiming for total gross proceeds of $6.6 million. Each unit comprises one share of common stock and one warrant, entitling the holder to purchase additional stock at an exercise price of $7.50. A 45-day option allows underwriters to purchase up to 158,400 additional shares to cover over-allotments. CEO Gareth Sheridan noted that this uplisting is a significant milestone for corporate visibility.
FAQ
What is the current stock price of Nutriband (NTRBW)?
What is Nutriband Inc.'s core business?
How does AVERSA technology work?
What sets Nutriband apart from its competitors?
In which markets is Nutriband active?
How does the company generate revenue?
What is the significance of the company’s intellectual property portfolio?
How does Nutriband ensure the safety of its transdermal products?
What role do strategic partnerships play in Nutriband’s operations?
